10.03.25 -- Accelerating Innovation In Clinical Trials And Advanced Therapies

This 11-12 November, Cell 2025 unites 1,000+ experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development. Gain insights across cell culture, therapy development, and CGT manufacturing, and learn from world-renowned leaders Bobby Gaspar (Orchard Therapeutics), Christof Von Kalle, (Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now

Clinical trial recruitment doesn’t have to be slow, costly, or unpredictable. Find the right recruit strategy and digital recruit model for your study.

Unlock the potential of advanced therapies with dedicated partnership and tailored manufacturing solutions, ensuring quality and efficiency from discovery through to delivery for next-generation treatments.

How did Quest help a leading pharmaceutical company overcome the data latency challenges associated with traditional EHR when recruiting eligible patients for a rare blood disorder drug?

Applied Biosystems TaqPath assays are the choice for probe-based qPCR assays for late-stage applications. These products offer the performance of TaqMan Assays while also providing the compliance needed for process development.

Trial@home, CHDR’s dedicated strategy for off-site clinical trials, enables investigators to collect information as trial participants go about their day to day activities.

Dive into subject matter experts who are integrated into the client’s project team, thus ensuring a more streamlined approach to providing the required support and/or recommending ways to achieve new efficiencies.

Learn about this integrated suite of services that spans global CRO capabilities, central laboratory services, and IVD & CDx regulatory development consulting.

We work as a single provider to empower patient and site participation in clinical trials. Our Integrated Trial Services team is dedicated to building strategic and unique combinations of solutions to accelerate trial timelines.

Eliminate delays and seamless regulatory alignment with expert consultants on study design, safety assessments, and regulatory positioning, drawing on the experience of former GLP study directors.

When a biopharmaceutical company developing a novel therapy for solid tumor cancers became concerned with rapid over-enrollment from within a single region, they employed a CRO for assistance.